Repertoire Genesis Inc. (Headquarters: Ibaraki, Osaka) has signed a contracted R&D agreement with the Japan Agency for Medical Research and Development (hereinafter "AMED") and has started the project through industry-academia-government collaboration that will explore the "Establishment of clinical manufacturing of highly functional NY-ESO-1-specific genome-edited T cells" as designated under AMED's Cyclic Innovation for Clinical Empowerment program (CiCLE).

View original content:Press Release